Will new approaches like gene & cell therapy provide a new treatment paradigm? As part of last week’s #BioDigital congress, James Sabry, our Head of Pharma Partnering, Harlan Robins of @AdaptiveBiotech & Federico Mingozzi of @spark_tx discussed the next generation of healthcare.
We’re launching our ImmuneCODE database with @Microsoft that will share the population-wide immune response to #COVID19. De-identified data is being made freely available to the global research community to advance solutions for the virus. https://t.co/933W4D7v7X #InThisTogether
Hear from our CEO Chad Robins and other industry leaders from @Amgen, @Novartis, @Microsoft, and @US_FDA for a panel on The Convergence of Health and Tech: Personalizing Medicine Beyond the Imaginable @BIOConvention#BIODigital. Moderated by @DShaywitz: https://t.co/kttHKSpgzm
So happy to be able to share the news of what we've been working on for the past 18 months.
We're very please to announce Day One Biopharmaceuticals (@DayOneBio), our Series A, our incredible team, and our lead program.
https://t.co/1sXLwDD6oX
The latest #IamBIO podcast has the scoop on how @AdaptiveBiotech is researching the immune system to determine exactly how the #coronavirus affects us – and how we can use this knowledge to end the pandemic. Listen: https://t.co/CsxCX2uJmp
Thank you @AndrewE_Dunn for spotlighting our #ImmuneRACE study with @Microsoft to map the immune response to #COVID19 to inform improved diagnostics. To learn about the ImmuneRACE study, visit: https://t.co/zMHVLO57Vx
Thank you @KerryNBC for getting the word out about our partnership with @Microsoft and our #ImmuneRACE study to rapidly map #COVID19 and inform improved diagnostics. To learn about the #ImmuneRACE study, visit https://t.co/3UwEdKRTeb
In case you missed it: Read CEO Chad Robins’ @timmermanreport article on extending our Immune Medicine Platform to fight #COVID19 and the role we all play in ending this pandemic. https://t.co/T4DitYQcxH
Managing an emerging company, and finding a way to extend an immune medicine platform with Dx and Rx potential. By Chad Robins, co-founder and CEO of @AdaptiveBiotech https://t.co/HbFXOKy18T